Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 3/20 | 0.54 |
| ▸ | VNN1 | O95497 | 11/20 | 0.46 |
| ▸ | GRM5 | P41594 | 3/20 | 0.44 |
| ▸ | ELANE | P08246 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.40 |
| ▸ | BTD | P43251 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30460400 | 1.00 | GSK3B (0.54) | GSK3BVNN1GRM5ELANEHSD17B10 | |
| SCHEMBL1847397 | 0.81 | GSK3B (0.59) | GSK3BVNN1GRM5HSD17B10 | |
| SCHEMBL30460451 | 0.81 | GSK3B (0.59) | GSK3BVNN1GRM5HSD17B10 | |
| SCHEMBL4110824 | 0.81 | GSK3B (0.52) | GSK3BVNN1GRM5ELANE | |
| SCHEMBL27517630 | 0.80 | NT5E (0.47) | GSK3BVNN1ELANE | |
| SCHEMBL4051434 | 0.80 | RAB9A (0.48) | GSK3B | |
| SCHEMBL310975 | 0.80 | GSK3B (0.51) | GSK3BVNN1GRM5ELANECLK4 | |
| SCHEMBL29130629 | 0.78 | PLOD2 (0.53) | GSK3B | |
| SCHEMBL29986565 | 0.78 | PLOD2 (0.53) | GSK3B | |
| SCHEMBL25310174 | 0.76 | GSK3B (0.50) | GSK3BVNN1GRM5BTD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250101013-A1 | FUNCTIONALIZED AMINOTHIAZOLES | LEADXPRO AG (CH) | 2025-03-27 | — | — | US | disclosed |
| EP-4466267-A1 | FUNCTIONALIZED AMINOTHIAZOLES | LeadXpro AG (CH) | 2024-11-27 | — | — | EP | disclosed |
| WO-2023139132-A1 | FUNCTIONALIZED AMINOTHIAZOLES | LEADXPRO AG (CH) | 2023-07-27 | — | — | WO | disclosed |
| WO-2023139132-A1 | FUNCTIONALIZED AMINOTHIAZOLES | LEADXPRO AG (CH) | 2023-07-27 | — | — | WO | disclosed |
| US-20090233938-A1 | Thiazole derivatives as a2b antagonists | NOVARTIS AG (CH) | 2009-09-17 | — | — | US | disclosed |
| EP-1709036-B1 | THIAZOLE DERIVATIVES AS A2B ANTAGONISTS | NOVARTIS AG (CH) | 2008-03-05 | — | — | EP | disclosed |
| EP-1709036-A1 | THIAZOLE DERIVATIVES AS A2B ANTAGONISTS | Novartis AG (CH) | 2006-10-11 | — | — | EP | disclosed |
| WO-2005070926-A1 | THIAZOLE DERIVATIVES AS A2B ANTAGONISTS | NOVARTIS AG (CH) | 2005-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250101013-A1 | FUNCTIONALIZED AMINOTHIAZOLES | ADORA2B, RB1, ADORA3 | GSK3B 3066/4885VNN1 4091/4885GRM5 1927/4885 |
| US-20090233938-A1 | Thiazole derivatives as a2b antagonists | ADORA2B, ADRA2B, AGTR2 | GSK3B 4388/4885VNN1 1743/4885GRM5 1915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.